HEALTH
EU urged to commit to “sustained” investment in cancer control

By Martin Banks

Investing in cancer control saves lives, strengthens health systems and boosts Europe’s economy.

Those are the findings of a new study by the European Cancer Organisation (ECO), developed as part of its Reach Higher for Cancer Care campaign and unveiled on Wednesday at the European Cancer Summit 2026 in Brussels.

Cancer remains one of Europe’s greatest health and economic challenges.

Every year, approximately 4.3 million people are diagnosed with this disease and nearly 2 million die from it. In 2023 alone, it imposed an estimated economic burden of €228 billion across 31 European countries through healthcare expenditure and lost productivity.

The new report, “Investing for high returns: the case for sustained commitment to cancer control”, gathers European evidence on the value of effective interventions.

The authors said the timing of this study “matters.”

Under the European Commission’s proposal for the EU’s next budget for 2028–2034, the standalone EU4Health programme would end, said the ECO.

Health, it adds, would lose its own budget and become part of a broader competitiveness fund.

Against this backdrop, ECO is calling for “sustained, predictable investment in cancer control” including a dedicated €2 billion fund for continued EU action in the next Multiannual Financial Framework (MFF).

This fund would, it says, build on the progress made through Europe’s Beating Cancer Plan and the EU Cancer Mission.

Among the key findings highlighted in the report:

  • Prevention saves lives and money: if every European country performed as well as the best performer in reducing cancer risk factors, it would prevent around 300,000 cancers and save €61 billion in healthcare costs every year.
  • Alcohol taxes pay back: when Lithuania raised alcohol excise duties in 2017, it gained €420 for every euro spent implementing the increase.
  • Better breast cancer screening saves lives: wider and better-attended breast cancer screening in France, Germany, Italy and Spain could save more than 3,200 lives a year, with higher participation among women already eligible offering the best value.
  • Where patients are treated matters: in Germany alone, treating every patient in a certified cancer centre could avoid 4,729 deaths a year.
  • Supporting survivors return to work boosts the economy: in the Netherlands, a return-to-work programme for cancer survivors would generate €92 million a year in productivity gains, for €15.4 million in costs.
  • Cancer research pays for itself: in the UK, every £1 of public and charitable cancer research funding yields around 40p in benefits each year, indefinitely.

The study finds similar returns from investing in the cancer workforce, infrastructure and efforts to reduce inequalities.

Commenting, Isabel Rubio, president of the European Cancer Organisation, said, “Too often, investment in cancer care is viewed simply as a cost, without recognising the substantial returns it brings to our societies and economies.”

She added, “This report demonstrates that investing in cancer control means more lives saved, better care for patients and stronger health systems. As Europe decides its next long-term budget, we must recognise not only the cost of investing in cancer control, but also the price of failing to do so.”

Further comment comes from Gilliosa Spurrier-Bernard – Co-Chair, ECO Patient Advisory Committee; Vice-President, Melanoma Patients Network Europe, who said, “The evidence shows that the benefits of investing in cancer control extend far beyond healthcare expenditure.

“From preventing cancer before it develops to supporting people in returning to work after treatment, well-designed interventions can deliver considerable human, social and economic returns. Sustained funding is essential to make these benefits available across Europe.”

About the author

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *

WordPress Cookie Plugin by Real Cookie Banner